Protalix BioTherapeutics (PLX) Common Equity (2009 - 2026)
Protalix BioTherapeutics (PLX) reported Common Equity of $71.4 million for Q2 2026, up 43.1% from $49.9 million a year earlier and up 6.2% from the prior quarter.
Powered by 
Analysis
Protalix BioTherapeutics (PLX) Common Equity (2009 - 2026) Analysis & Trends
At the end of FY2025, Protalix BioTherapeutics posted Common Equity of $48.23 million, up 11.6% from FY2024.
- By year, Common Equity came in at $43.21 million in FY2024 (+28.7%), $33.57 million in FY2023, -$10.64 million in FY2022 and -$6.04 million in FY2021.
- The Q2 2026 figure ranks as the highest quarterly Common Equity in data going back to Q2 2010.
- Year over year, Common Equity has now increased in each of the last seven quarters, with growth averaging 38.3% over the last eight quarters.
- The high point for year-over-year Common Equity in five years was Q2 2025 (growth of 74.6%); the low point was Q2 2024 (a decline of 26.7%).
- Per Business Quant data, the three quarters before Q2 2026 came in at $67.23 million (Q1 2026), $48.23 million (Q4 2025) and $52.91 million (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,348.13 Bn | 1,321.74 Bn | 20.46 Bn | 40.27 Bn |
| 2 | Johnson & Johnson | 675.90 Bn | 595.76 Bn | 17.30 Bn | 81.53 Bn |
| 3 | AbbVie | 519.45 Bn | 487.50 Bn | 13.12 Bn | -4.58 Bn |
| 4 | Merck | 364.95 Bn | 327.95 Bn | 13.19 Bn | 44.95 Bn |
| 5 | Novartis Ag | 311.58 Bn | 285.16 Bn | - | - |
| 6 | Astrazeneca | 289.34 Bn | 262.94 Bn | 13.26 Bn | 51.81 Bn |
| 7 | Amgen | 251.64 Bn | 203.30 Bn | 7.58 Bn | 14.35 Bn |
| 8 | Gilead Sciences | 212.05 Bn | 187.07 Bn | 6.73 Bn | 13.04 Bn |
| 9 | Pfizer | 167.35 Bn | 115.00 Bn | 12.56 Bn | 89.30 Bn |
| 10 | Protalix BioTherapeutics | 230.43 Mn | 59.88 Mn | 14.05 Mn | 80.55 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2026 | 80.55 Mn |
| Jun 30, 2026 | 71.40 Mn |
| Mar 31, 2026 | 67.23 Mn |
| Dec 31, 2025 | 48.23 Mn |
| Sep 30, 2025 | 52.91 Mn |
| Jun 30, 2025 | 49.90 Mn |
| Mar 31, 2025 | 45.21 Mn |
| Dec 31, 2024 | 43.21 Mn |
| Sep 30, 2024 | 32.44 Mn |
| Jun 30, 2024 | 28.58 Mn |
| Mar 31, 2024 | 29.79 Mn |
| Dec 31, 2023 | 33.57 Mn |
| Sep 30, 2023 | 38.25 Mn |
| Jun 30, 2023 | 39.00 Mn |
| Mar 31, 2023 | 1.01 Mn |
| Dec 31, 2022 | -10.64 Mn |
| Sep 30, 2022 | -11.51 Mn |
| Jun 30, 2022 | -9.89 Mn |
| Mar 31, 2022 | -7.49 Mn |
| Dec 31, 2021 | -6.04 Mn |
API Access
Protalix BioTherapeutics Common Equity API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=common-equity&ticker=PLX&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "common-equity", "ticker": "PLX", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=common-equity&ticker=PLX&period=max&api_key=YOUR_API_KEY");
const data = await res.json();